Trade Report: The California State Teachers Retirement System Increases Position in Revance Therapeutics Inc. (RVNC)

The California State Teachers Retirement System Increases Position in Revance Therapeutics Inc. (RVNC)

California State Teachers Retirement System boosted its position in shares of Revance Therapeutics Inc. (NASDAQ:RVNC) by 10.5% during the second quarter, Holdings Channel reports. The firm owned 42,870 shares of the biopharmaceutical company’s stock after buying an additional 4,076 shares during the period. California State Teachers Retirement System owned about 0.15% of Revance Therapeutics worth $583,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Royal Bank of Canada boosted its stake in shares of Revance Therapeutics by 250.1% in the first quarter. Royal Bank of Canada now owns 20,220 shares of the biopharmaceutical company’s stock worth $353,000 after buying an additional 14,444 shares during the period. Alps Advisors Inc. boosted its stake in shares of Revance Therapeutics by 26.7% in the second quarter. Alps Advisors Inc. now owns 39,990 shares of the biopharmaceutical company’s stock worth $544,000 after buying an additional 8,431 shares during the period. Vivo Capital LLC purchased a new stake in shares of Revance Therapeutics during the first quarter worth approximately $1,886,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Revance Therapeutics during the first quarter worth approximately $1,447,000. Finally, Geode Capital Management LLC boosted its stake in shares of Revance Therapeutics by 8.8% in the first quarter. Geode Capital Management LLC now owns 140,040 shares of the biopharmaceutical company’s stock worth $2,445,000 after buying an additional 11,322 shares during the period.

Shares of Revance Therapeutics Inc. (NASDAQ:RVNC) traded up 0.51% during mid-day trading on Friday, reaching $15.65. The company had a trading volume of 89,305 shares. Revance Therapeutics Inc. has a one year low of $12.54 and a one year high of $42.41. The company’s market capitalization is $445.77 million. The company has a 50 day moving average price of $15.33 and a 200 day moving average price of $16.15.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.02. The business had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.06 million. Revance Therapeutics had a negative net margin of 28,586.33% and a negative return on equity of 40.44%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. On average, analysts anticipate that Revance Therapeutics Inc. will post ($3.53) EPS for the current year.

A number of brokerages have commented on RVNC. SunTrust Banks Inc. reduced their price objective on Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, June 14th. Zacks Investment Research raised Revance Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Wednesday, July 13th. Brean Capital reissued a “hold” rating on shares of Revance Therapeutics in a research note on Thursday, June 23rd. Piper Jaffray Cos. reissued an “overweight” rating and issued a $35.00 price objective (down previously from $54.00) on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Finally, Guggenheim reaffirmed a “buy” rating and set a $55.00 target price on shares of Revance Therapeutics in a research report on Tuesday, June 14th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Revance Therapeutics currently has an average rating of “Buy” and a consensus price target of $39.88.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Related posts

Leave a Comment